‘Multi-node supply chains’ are the future, in a ‘multi-polar pharma world’

China, India, and the Middle East are all playing their role in shifting the geographical centre of production and innovation, the three regions emerging as particularly important to the global pharmaceutical supply chain

Frank van Gelder, secretary general of Pharma.Aero, said a fracturing of the supply chain with a more geographically diffuse network of production, healthcare providers, and clinical centres could create new opportunities for airfreight and specialist logistics providers.

“China is no longer only a major source of pharmaceutical ingredients and manufacturing capacity; it is becoming an increasingly important centre for biotechnology, clinical development, and innovative medicines,” he told The Loadstar.

“India remains essential to generics and manufacturing, while expanding its innovative capabilities; Europe and North America remain central, but innovation and production are becoming more geographically distributed.

This story was originally published by The Loadstar. Read the full story at The Loadstar →